Syncrosome invites you to visit us at Bio-Europe, November 7th to November 9th 2016, in Cologne, Germany. Emmanuelle Bettendorf, our Business Developer would be delighted to meet you their and discuss your in vivo preclinical projects. We can give you advice about our in vivo efficacy, CNS-PK...
The 2nd Drug Discovery Innovation Programme will feature 2 days of interactive presentations, poster presentation and networking opportunity, in Hamburg (Germany) from 20 to 21st of October. This conference will offer a complete programme focusing on preclinical animal models, breakthrough technologies, in vivo and in...
Syncrosome, participated last week to the Neuroscience R&D Technologies Conference in London, to present key Parkinson's data. It was 2 very interesting days spent to discuss about the new advances in Imaging of Neurodegeneration, Alzheimer and Parkinson’s Disease and Drug Discovery, New trends in Preclinical animal...
L-DOPA remains the most effective therapy in the management of the motor symptoms of Parkinson's disease (PD). However, chronic treatment with levodopa is associated with the risk of development of motor fluctuations such as choreic and dystonic abnormal and involuntary movements affecting mainly the upper...
As you know Syncrosome is a preclinical CRO managing efficacy in vivo/ in vitro studies with more than 15 disease models validated in house and reproducible. Syncrosome is involved in Central Nervous System activities for 16 years with a specific department dedicated to several CNS disease...
Syncrosome is just launching its new website. This is the result of the collaboration between Syncrosome’s internal team, consultants and customers: www.syncrosome.com. Thank you for your collaboration, and we hope you will find all information you are looking for! Please do not hesitate to visit it and...
Syncrosome, a Preclinical CRO specialized in in vivo efficacy experiments, is pleased to welcome our new colleague, Caroline Babuleaud-Casano as our new Technical Manager. Caroline hold 2 MSc., 1 in Neurosciences and 1 in Neuro-pharmacology. During her 10 years professional experience, she has been working on various...
Vaccination is increasingly being investigated as a potential treatment for synucleinopathies, a group of neurodegenerative diseases including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies associated with α-synuclein pathology. All lack a causal therapy. Development of novel, disease-altering treatment strategies is urgently needed....
Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies, have all something in common. They all belong to a group of neurodegenerative diseases called synucleinopathies, including preclinical Parkinson, characterized by the abnormal accumulation of aggregates of α-synuclein protein in neurons, nerve fibres or glial...
Researchers from the CHU Research centre in Quebec have shown that diet can play a neuroprotective role in a preclinical Parkinson mouse model. They investigated the effects of a omega-3 polyunsaturated fatty acids-enriched diet, in the form of docosahexaenoic acid (DHA), on damaged neurons. C57BL/6...